Drug Profile
Gossypol - Bioenvision
Alternative Names: VelostanLatest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator Cardiff University
- Developer Sanofi
- Class Contraceptives; Sesquiterpenes
- Mechanism of Action Oxygen radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Bladder cancer; Prostate cancer
- Discontinued Adrenal cancer; Breast cancer
Most Recent Events
- 08 Apr 2011 Genzyme Corporation has been acquired by sanofi-aventis
- 23 Oct 2007 Bioenvision has been acquired by Genzyme Corporation
- 30 Jun 2006 Suspended - Phase-I for Bladder cancer in USA (PO)